Louise has worked within the NHS since 2004, previously a member of the Fundraising Team at Velindre Cancer Centre and then moved on to become part of the Clinical Trials Team where she set up and supported the running of a large portfolio of clinical trials. Her role within WCRC is Project Officer, which involves co-ordinating and managing various projects within the clinical work package that concentrates on early phase and randomised controlled trials.
"I really enjoy helping others and clinical research is becoming a vital part of a patient’s cancer journey so to be part of the implementation and promotion of research excellence that benefits patients across Wales and beyond is really rewarding."
Dr Mark Davies is a Consultant Medical Oncologist, specialising in breast cancer at the South West Wales Cancer Centre (SWWCC) in Swansea and Honorary Associate Professor at Swansea University Medical School.
Mark is dually accredited in medical oncology and clinical genetics. In his role as a clinical geneticist, he has focused on the care of inherited tumour predisposition syndromes and has established clinics to co-ordinate the care needed by patients with tuberous sclerosis, a rare tumour predisposition syndrome, and for children with an inherited risk of cancer.
His research interests focus on novel means to target mTOR signalling in cancer and on integrating genomics into mainstream oncology. He is a member of the National Cancer Research Institute Children’s Cancer Clinical Research Group and the All Wales Genetic Oncology Group. He is currently the local lead investigator for several breast cancer trials and is systemic therapy research lead at SWWCC.
Richard Adams is Professor of Cancer Clinical Trials, Director of the CRUK core funded Centre for Trials Research (Cancer Division), Clinical Director of the Wales Cancer Bank and Honorary Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute (NCRI) radiotherapy and early phase national CTRad research group , Chair of the CRUK Clinical Expert Review Panel and is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer), ESMO and ARCAD.
Richard is a Chief investigator. He leads on radiotherapy quality assurance programmes for UK anal and rectal cancer radiotherapy trials. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Cancer Care link with Sierra Leone.
Dr Clarkson is Reader in Cancer Studies at Cardiff University and was Translational Theme lead for WCRC until 2020. In his new role as Science Director of the Wales Cancer Bank, which received independent infrastructure funding from HCRW in 2020, Dr Clarkson’s involvement on the WCRC Executive Committee will provide an important line of communication between the activities of WCRC and the Wales Cancer Bank, ensuring unfettered access of cancer samples to the WCRC research community. The shared vision of WCB and WCRC for an integrated approach to cancer research in Wales, involving the collation and integration of clinical, genomic and imaging data with patient’s biological samples, lies at the heart of their joint aspirations for improving the health prospects of cancer patients in Wales.
Richard Clarkson is Senior Lecturer of cancer research in the School of Biosciences and is academic mentor for the research fellows in the European Cancer Stem Cell Research Institute.
Richard received his PhD from the Faculty of Medicine, University of Manchester and carried out research at the Universities of Queensland, Edinburgh and Cambridge before moving to Cardiff in 2005. Having worked for more than 10 years on the biology of the mammary gland and the regulation of epithelial cell apoptosis, Richard’s research group now focuses on applying this knowledge to identify novel therapeutic strategies to eliminate or modify the cancer cells responsible for the spread of tumours around the body – often referred to as the cancer stem cells.
Current responsibilities and positions:
Deputy Director of the European Cancer Stem Cell Research Institute https://www.cardiff.ac.uk/cancer-stem-cell
Science Director of Wales Cancer Bank (WCB): http://www.walescancerbank.com
Theme Lead for Wales Cancer Research Centre (WCRC): https://www.walescancerpartnership.com/wcrc/
Vice-chair of WCRC Multi-disciplinary Research Group for Prostate Cancer
Member of Scientific Advisory Board for Breast Cancer Now: http://breastcancernow.org
Research Integrity Lead, Cardiff University College of Biological Lifesciences
Academic Team Lead, School of Biosciences, Cardiff University
Phase 1 Trial Lead, Senior Lecturer and Consultant Medical Oncologist, Cardiff University and Velindre Cancer Centre.
Rob is Speciality Lead for Cancer in Wales, Lead for Phase 1 trials in Wales, and Clinical Research Director at the Velindre NHS Trust. He comes from a research background having carried out a PhD in Cancer Research before studying Medicine in Oxford. Having completed Oncology training, he carried out a CRUK Clinician Scientist post before being appointed as Senior Lecturer in Medical Oncology in Cardiff. Since opening Wales’ first ‘First in Human’ trial approximately 8 years ago, Robert has led the development of the portfolio and has been Principal Investigator around 20 Phase 1 trials being delivered through the Velindre Cancer Research Trials Unit. He is also Chief Investigator on two other Investigator Led trials ‘FAKTION’ and ‘FURVA’, the former having reported Orally at ASCO 2019 and been published in Lancet Oncology in 2020. He also sits on the NCRI Strategy Advisory Group and is a member of the NCRI Colorectal and Early Phase Clinical Study Groups. Rob has also been a member CRUK Combinations Alliance Committee until April 2020.
Steve is the co-lead of the Early Phase Clinical Trials work package. He is an academic clinical haematologist and combines the role of Clinical Reader in the Institute of Cancer and Genetics at Cardiff University School of Medicine with clinical work as a Consultant Haematologist at the University Hospital of Wales where he serves as haematological cancer lead clinician.
Steve's clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia, the myeloproliferative neoplasms and myelodysplastic syndromes. His chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies including 'back-to-bench' laboratory projects running alongside clinical trials. He serves as principal investigator for an evolving portfolio of early and later phase clinical studies.
Steve is extensively involved in the development of clinical research at a national level through activities within the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. His other roles include Cardiff lead for the Trials Acceleration Programme (now funded by Cure Leukaemia) and lead of Cardiff School of Medicine medical undergraduate haematology teaching.
Alan is a Reader in Translational Virotherapies based within the Division of Cancer and Genetics at Cardiff University School of Medicine. Alan has long standing experience in developing targeted, advanced therapeutics, gained from previous positions at the University of Birmingham (1998 – 2003), King’s College London (2003 – 2005) and the University of Glasgow (2005 – 2013).
His team study the adenovirus, using detailed information about how viruses interact with cells to develop targeted, bespoke virotherapies for a diverse array of cancer types. His team are supported by programmatic funding from Cancer Research UK, as well as funding from Cancer Research Wales, Tenovus Cancer Care and Knowledge Economy Skills Scholarship (KESS 2).
Amongst his varied other roles, Alan is a long standing, founding member of the British Society for Gene and Cell Therapy (BSGCT). He has been an elected board member since 2014 – the first (and only) BSGCT board member based in Wales, and in 2020 became treasurer for the society. In 2017 Alan established an active BSGCT subcommittee committed to the development of Early Career Researchers within the Gene and Cell Therapy field, which now runs as an annual networking and careers focussed meeting.
Julie was a Research Partner at the centre for four years before taking up the Lead Lay Research Partner position in 2020. Her interests and experience within the cancer field lie mainly in the bowel cancer area and in prevention and early diagnosis of cancer generally, and her involvement is both within Wales and in some of the wider UK cancer research activities.
Her activities related to Wales Cancer Research include: